A potential place for off-label mTOR inhibition by everolimus could be relapsed/refractory classical Hodgkin lymphoma, where novel agents are warranted for patients failing PD-1 inhibitors either as monotherapy or in combinations or in the context of metronomic therapy [93]. This evidence concerns the gene MTOR and Hodgkins lymphoma.